

“This reprint might contain references to “Merck” or “Merck KGaA”, which refer to (1) Merck KGaA, Darmstadt, Germany; (2) an affiliate of Merck KGaA, Darmstadt, Germany; or (3) one of the businesses of Merck KGaA, Darmstadt, Germany, which operate as EMD Serono in the healthcare, MilliporeSigma in the life science and EMD Electronics in the electronics business in the U.S. and Canada.

There are two different, unaffiliated companies that use the name “Merck”. Merck KGaA, Darmstadt, Germany, which is providing this content, uses the firm name “Merck KGaA, Darmstadt, Germany” and the business names EMD Serono in the healthcare, MilliporeSigma in the life science and EMD Electronics in the electronics business in the U.S. and Canada. The other company, Merck & Co., Inc. holds the rights in the trademark “Merck” in the U.S. and Canada. Merck & Co., Inc. is not affiliated with or related to Merck KGaA, Darmstadt, Germany, which owns the “Merck” trademark in all other countries of the world.”

# Characteristics of Relapsing Multiple Sclerosis Patients Treated with Cladribine Tablets in Five European Countries: An Analysis of Multi-Year Chart Review Data

**Feng Zeng<sup>1</sup>, Schiffo L. Wong<sup>1</sup>, Gerard Harty<sup>2</sup>, Ekaterina Maslova<sup>3</sup>, René Schade<sup>3</sup>, Bill Row<sup>3</sup>**

<sup>1</sup>EMD Serono Research & Development Institute, Inc., Billerica, MA, USA, a business of Merck KGaA, Darmstadt, Germany; <sup>2</sup>Merck KGaA, Darmstadt, Germany; <sup>3</sup>ICON Plc

# Disclosures

This study was sponsored by EMD Serono, an affiliate of Merck KGaA, Darmstadt, Germany.

- **EM, RS, BR** are employees of ICON plc, which received funding from EMD Serono to conduct the study.
- **FZ, SLW** are employees of EMD Serono, Inc., Billerica, MA, USA, an affiliate of Merck KGaA, Darmstadt, Germany
- **GH** is employee of Merck KGaA, Darmstadt, Germany



## INTRODUCTION

- MS is a debilitating disease with multifaceted symptoms that impacts millions of patients globally. DMDs are critical in slowing disease progression and improving patients' quality of life.
- In 2017, cladribine tablets were approved for highly active relapsing RMS in the European Union. Clinical care delivery in RMS can be informed by understanding the profile of RMS patients treated with cladribine tablets in a real-world setting.



## OBJECTIVES

To describe profile of persons with RMS treated with cladribine tablets in the five largest countries of the European Union since market authorization from October 2017 to June 2019.



## METHODS

Patient Population/Study design etc.

The Ipsos Healthcare Multiple Sclerosis Monitor collects data from 300 neurologists across France, Germany, Italy, Spain, and the United Kingdom (U.K.) on their MS practices and patient information.

Descriptive statistics were used to summarize patient attributes such as age and sex, country, Expanded Disability Status Scale (EDSS) score as of cladribine initiation, DMD history, and physician reason for prescribing cladribine tablets.




# RESULTS

<b>Patient Profile</b>	
<b>Total Number of Patients</b>	<b>182 (100%)</b>
<b>Geographic Distribution</b>	
UK	42 (23.1%)
Germany	82 (45.1%)
Italy	26 (14.3%)
Spain	26 (14.3%)
France	6 (3.3%)
<b>Patients with EDSS Data</b>	
Median EDSS (25 percentile, 75 percentile)	3 (1.5, 4.5)
<b>RRMS Diagnosis</b>	
	<b>172 (94.5%)</b>



# RESULTS

## DMDs before Cladribine Tablets



**More than 1/3 patients were naïve to DMDs**

## Most Frequent Reasons for Using Cladribine Tablets

Reasons	Percentage
Efficacy for active/ highly active disease	31.3%
Efficacy in stabilising or preventing new lesions	15.9%
Efficacy for relapses	8.8%
Frequency of administration	8.2%
Patient decision	7.1%
Best benefit to risk profile	6.0%

**Efficacy was the most frequently cited reason for using cladribine**





## CONCLUSIONS



In this real-world analysis of persons treated with cladribine tablets in the EU5, more than 1/3 of persons were naïve to DMDs.



The most frequently cited reason for physicians to prescribe cladribine tablets was efficacy for active/highly active disease.